Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.

Back to Search
Print
Bookmark Trial

NCT00368745

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
San Pedro de Montes de Oca, San José, 00, Costa Rica
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Generalized Anxiety Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Provide written informed consent

- 18-65 years old

- male and female

- A primary lifetime diagnosis of DSM-IV-TR (2000) GAD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnant or lactating women


- History of non-response to alprazolam, other benzodiazepines, gabapentin or pregabalin
given for the treatment of anxiety as indicated by a (screening or baseline) Hamilton
Anxiety Scale (HAM-A) score > 18

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Generalized Anxiety DisorderAn Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers NCT00537615
  1. New Haven, Connecticut
Male
18 Years+
years
MULTIPLE SITES
Generalized Anxiety DisorderEvaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body NCT00800280
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Generalized Anxiety Disorder6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD) NCT00738738
  1. Orlando, Florida
  2. Prairie Village, Kansas
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Generalized Anxiety DisorderA 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) NCT00735267
  1. Birmingham, Alabama
  2. Litchfield Park, Arizona
  3. Arcadia, California
  4. Beverly Hills, California
  5. Costa Mesa, California
  6. Costa Mesa, California
  7. Encino, California
  8. Escondido, California
  9. Murrieta, California
  10. National City, California
  11. Newport Beach, California
  12. Orange, California
  13. Pasadena, California
  14. Redlands, California
  15. San Diego, California
  16. San Diego, California
  17. Sherman Oaks, California
  18. Temecula, California
  19. Upland, California
  20. Wildomar, California
  21. Denver, Colorado
  22. Hamden, Connecticut
  23. Norwich, Connecticut
  24. Altamonte Springs, Florida
  25. Ft. Myers, Florida
  26. Jacksonville, Florida
  27. Maitland, Florida
  28. Miami, Florida
  29. Miami, Florida
  30. Orange City, Florida
  31. Orlando, Florida
  32. South Miami, Florida
  33. West Palm Beach, Florida
  34. Atlanta, Georgia
  35. Atlanta, Georgia
  36. Marietta, Georgia
  37. Libertyville, Illinois
  38. Naperville, Illinois
  39. Park Ridge, Illinois
  40. Greenwood, Indiana
  41. Terre Haute, Indiana
  42. Overland Park, Kansas
  43. Prairie Village, Kansas
  44. Wichita, Kansas
  45. Owensboro, Kentucky
  46. Lake Charles, Louisiana
  47. Baltimore, Maryland
  48. Belmont, Massachusetts
  49. Boston, Massachusetts
  50. Fall River, Massachusetts
  51. Haverhill, Massachusetts
  52. Pittsfield, Massachusetts
  53. Omaha, Nebraska
  54. Las Vegas, Nevada
  55. Nashua, New Hampshire
  56. Albuquerque, New Mexico
  57. Bronx, New York
  58. Brooklyn, New York
  59. New York, New York
  60. New York, New York
  61. New York, New York
  62. Rochester, New York
  63. Raleigh, North Carolina
  64. Columbus, Ohio
  65. Dayton, Ohio
  66. Toledo, Ohio
  67. Toledo, Ohio
  68. Bethany, Oklahoma
  69. Oklahoma City, Oklahoma
  70. Oklahoma City, Oklahoma
  71. Portland, Oregon
  72. Salem, Oregon
  73. Allentown, Pennsylvania
  74. Media, Pennsylvania
  75. Norristown, Pennsylvania
  76. Philadelphia, Pennsylvania
  77. Lincoln, Rhode Island
  78. Columbia, South Carolina
  79. Memphis, Tennessee
  80. Memphis, Tennessee
  81. Austin, Texas
  82. Dallas, Texas
  83. Dallas, Texas
  84. DeSoto, Texas
  85. Houston, Texas
  86. Houston, Texas
  87. Lake Jackson, Texas
  88. San Antonio, Texas
  89. Woodstock, Vermont
  90. Charlottesville, Virginia
  91. Seattle, Washington
  92. Middleton, Wisconsin
  93. Waukesha, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy.
Brief Summary GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6 weeks. Subjects return weekly for assessment of safety/tolerability of pregabalin vs placebo as well as for assessment of anxiety and benzodiazepine withdrawal symptoms. Subjects successfully able to discontinue alprazolam, will continue 6 weeks of treatment with pregabalin vs placebo (free of benzodiazepine use). The efficacy and safety of pregabalin vs placebo for anxiety symptoms and ability to discontinue/remain free of alprazolam will be compared among pregabalin and placebo treated groups. Hypothesis is that a greater proportion of subjects will be successful in discontinuing and remaining free from benzodiazepines who were treated with pregabalin as compared to subjects treated with placebo.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Generalized Anxiety Disorder
Intervention  ICMJE
  • Drug: Pregabalin
    GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
    Other Name: Lyrica
  • Drug: Placebo
    GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
Study Arms  ICMJE
  • Active Comparator: Pregabalin
    Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
    Intervention: Drug: Pregabalin
  • Placebo Comparator: Placebo
    Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 28, 2009)		108
Original Enrollment  ICMJE
 (submitted: August 23, 2006)		80
Actual Study Completion Date  ICMJE August 2008
Actual Primary Completion Date August 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Provide written informed consent
  • 18-65 years old
  • male and female
  • A primary lifetime diagnosis of DSM-IV-TR (2000) GAD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)

Exclusion Criteria:

  • Pregnant or lactating women
  • History of non-response to alprazolam, other benzodiazepines, gabapentin or pregabalin given for the treatment of anxiety as indicated by a (screening or baseline) Hamilton Anxiety Scale (HAM-A) score > 18
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Costa Rica,   Czech Republic,   France,   Guatemala,   Italy,   Mexico,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00368745
Other Study ID Numbers  ICMJE A0081092
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP